Hengrui Pharmaceuticals reports new BCL6 degradation inducers
AI Briefing
- • Hengrui Pharmaceuticals discovers new BCL6 degradation inducers for autoimmune disease and cancer treatment.
- • The new compounds may have therapeutic potential for treating autoimmune diseases and cancers.
- • Hengrui Pharmaceuticals' research aims to develop novel treatments using BCL6 degradation inducers.
Source Summary
Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have identified new BCL6 degradation inducers potentially useful for the treatment of autoimmune disease and cancer.
Advertisement